黑料吃瓜群网

Australian AI healthcare company 鈥檚 non-invasive diagnostic support solution to detect coronary artery disease, , has commenced its聽first market pilot with Perth-based radiology practice .

Developed through a collaboration with the , the and the , the solution analyses cardiac CT scans using AI algorithms, producing a 3D image and report that provides disease detection.

Salix detects and assesses atherosclerotic plaque in a patient鈥檚 arteries, the substrate of most heart attacks, and is testing algorithms to further define the most vulnerable plaques.

Envision cardiologist Dr Lawrence Dembo said,聽鈥淔rom the time a scan is completed, within a few minutes I can select the patient of highest interest, and all the vessels are tracked, lesions are identified and assessed, the calcium score is calculated and a report is written. All before I touch the keyboard.鈥�

The solution can automatically assess Vulnerable Plaque, Stenosis, Calcium Score and total plaque burden, from a single scan at the point of care, in around 15 minutes. It is said to provide a detailed and accurate analysis of key CAD biomarkers from one CT scan.

Artrya Chief Medical Officer Professor Dwivedi said Salix unlocks the capability to triage patients into risk categories, identifying those patients who require further clinical assessments and those who can be reassured.

Artrya聽is planning an unrestricted launch across Australia for early 2022, with options for trial potentially sooner. The company intends to expand into targeted international markets in 2022, once international regulatory approvals have been acquired.

Image credit: 漏stock.adobe.com/au/7activestudio